One non-invasive scan, forty-nine channels, under seven minutes. For research, that means a fuller picture of every participant and far more data to build hypotheses around. For trials, a clearer read on whether a therapy is working — and earlier warning when it isn't safe.
A more comprehensive view of the participant, and more data to build hypotheses around — captured densely enough to actually use.
Explore research studies → Track B · § 04 Clinical trialsMore robust, safer, and more cost-effective — a clearer picture of whether a therapy is working, with safety signals caught earlier.
Explore clinical trials →Aurorus was built as a measurement layer, not for any one study design. A non-invasive scan, under seven minutes, no phlebotomy — producing a quantitative read of physiological state across forty-nine channels.
Research and trials ask different things of that read. Studies want breadth — more dimensions, captured more often, on more participants. Trials want decision quality and safety — a clearer answer on efficacy, and an earlier one on harm.
In research the constraint has rarely been ideas. It's data — its breadth, its frequency, and the friction of collecting it. Aurorus has the potential to loosen all three at once.
A single read resolves activity across forty-nine anatomical channels at once — a system-level portrait of the participant rather than a handful of isolated analytes. Studies capture the whole physiological surface in one pass, including dimensions that single-marker assays were never designed to see.
Because the scan is non-invasive and takes minutes, dense longitudinal sampling becomes practical — weekly, daily, or before-and-after a single exposure, at frequencies that serial blood draws make cost- and burden-prohibitive. Studies trade sparse snapshots for a continuous physiological trajectory.
A high-dimensional, repeatable readout is fertile ground for discovery. Researchers can surface patterns and correlations across channels, cohorts, and time — generating hypotheses from the data itself, then testing them on the same instrument that raised them. Findings stay comparable across studies, sites, and populations.
Non-invasive, portable, and operable without a phlebotomist, the scan reaches participants who decline or can't tolerate blood draws — and runs in homes, remote sites, and decentralized arms. Lower participant burden means better retention and bigger, more representative cohorts.
Every participant, at every visit, leaves behind a forty-nine-channel physiological record — not a single lab value, but a structured, archivable, comparable map of state. The hypothesis you'll want to test next year is already in the data you collect today.
Dense, low-burden monitoring across long follow-up — where conventional retesting frequency is the limiting factor on what the study can observe.
A multidimensional readout to characterize how a state or exposure moves physiology — and to surface candidate signals worth a dedicated study.
A consistent measurement standard across sites and populations, so records collected years and continents apart remain comparable.
The same measurement, pointed at the questions a trial lives and dies by — does the therapy work, and is it safe.
Aurorus has the potential to make clinical trials more robust, safer, and more cost-effective. The scan could give sponsors a clearer picture of whether a therapy is working — and may be able to catch safety signals earlier, before adverse effects reach clinical thresholds.
The aim is for trials to reach decisions on stronger evidence, with less risk to participants and less capital spent on candidates that aren't performing.
A quantitative, multidimensional read of physiological response — captured before, during, and after intervention on the same instrument. Sponsors could see whether a therapy is actually moving the participant, beyond what a single endpoint or self-report reveals — with the aim of helping trials reach decisions on stronger evidence.
Because the scan can register physiological change before it surfaces as a clinical event, it may be able to flag deterioration earlier — potentially before adverse effects reach clinical thresholds, giving investigators a chance to intervene, adjust, or stop sooner, with less risk to participants.
Earlier, clearer signal could mean less money spent carrying under-performing candidates through expensive late phases. Non-invasive, decentralized-ready scans also cut per-visit assessment cost and the logistics of serial blood collection across the cohort.
The same paired-read protocol fits wherever a trial needs to know what a therapy is doing to the participant.
Dense physiological monitoring of early cohorts — aiming to help surface tolerability signals before they escalate, and to inform dose decisions with more than vitals and labs alone.
A sensitive, multidimensional efficacy read aimed at detecting whether a therapy is working and in whom — to help sharpen go / no-go decisions before committing to pivotal scale.
A consistent, decentralized-ready endpoint across large, distributed cohorts — extending into post-market and registry follow-up on the same measurement standard.
Tell us what you're investigating. We'll route the conversation to the right person on our research team.
For pharma, biotech, and device sponsors evaluating Aurorus as a trial endpoint.
Schedule a sponsor briefing → Route · 02For contract research and operations teams designing decentralized or serial-read protocols.
Discuss study design → Route · 03For investigators and research sites building cohorts, registries, or mechanistic studies.
Research partnership inquiry → Route · 04For multi-site consortia and grant-funded programs standardizing measurement across sites.
Program inquiry →Aurorus is an electrophysiological measurement system cleared by the FDA under De Novo classification (DEN150004). It is not an in-vitro diagnostic and does not replace clinical judgment, protocol-defined primary endpoints, or laboratory testing where required. Use of Aurorus measurements as a study endpoint is determined by the investigator and study protocol.